Elizabeth
Jungman
J.D., M.P.H.
Leadership Role
Chief of Staff - Office of the Commissioner
![Elizabeth Jungman, J.D., M.P.H.](https://public4.pagefreezer.com:443/content/FDA/04-02-2024T13:07/https://www.fda.gov/files/styles/person_portrait_large/public/ElizabethJungman_1913_Flag-800x800.jpg?itok=SphZl0ZT)
As Chief of Staff of the FDA, Elizabeth Jungman, J.D., M.P.H. oversees the day-to-day management of the agency and leads agency activities on major initiatives. In this role, she provides strategic direction to senior leadership to advance the FDA’s policy priorities and works closely with the leadership of all FDA product centers and field operations to support the successful implementation of agency policies. She serves as the Commissioner’s direct liaison to other executive agencies and organizations and engages across government on critical public health initiatives. Ms. Jungman also plays a key role in legislative engagement, communications and stakeholder outreach.
Prior to the Chief of Staff role, Ms. Jungman worked in the FDA’s Center for Drug Evaluation and Research as Associate Director for Policy and Director of the Office of Regulatory Policy, helping to oversee the development of regulations, policies and procedures for human prescription and over-the-counter (OTC) drugs.
Before joining the FDA in 2019, Ms. Jungman worked for The Pew Charitable Trusts, first as Director of Drug Safety and Innovation, then as Director of Public Health Programs. She led projects on important issues such as antibiotic innovation and stewardship in both humans and animals; the FDA’s regulation of laboratory developed tests, regenerative medicine therapies, OTC drug products, dietary supplements and compounding; and policy to address substance use disorder.
From 2011 to 2013, Ms. Jungman was a Senior Health Policy Adviser with the U.S. Senate Committee on Health, Education, Labor, and Pensions (HELP). While on the HELP Committee, she advised on legislative matters related to drugs, devices, veterinary products, foods and cosmetics, and played a crucial role in drafting and negotiating the Food and Drug Administration Safety and Innovation Act of 2012 and other health- and drug-related legislation, including pandemic preparedness, drug compounding and supply chain security.
Earlier in her career she was a member of a Washington, D.C.-based law firm advising on a broad range of food and drug, and health care matters.
Ms. Jungman holds a bachelor’s in biology from Harvard College, a law degree from Georgetown University Law Center, and a master’s in public health from Johns Hopkins School of Public Health.